Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA™ or Zoledronic Acid

NCT01967160 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2560

Last updated 2023-06-22

No results posted yet for this study

Summary

A non-interventional study to assess incident rates of Osteonecrosis of the Jaw and Infections leading to hospitalization in Cancer patients treated with XGEVA™ in Sweden, Denmark and Norway.

Conditions

  • Osteonecrosis of the Jaw
  • Infection Leading to Hospitalization

Sponsors & Collaborators

  • Aarhus University Hospital

    collaborator OTHER
  • Amgen

    lead INDUSTRY

Principal Investigators

  • MD · Amgen

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-02
Primary Completion
2019-08-05
Completion
2019-08-05

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01967160 on ClinicalTrials.gov